ASGCT and the Orphan Therapeutics Accelerator launched CGTxchange, an AI-enhanced clearinghouse intended to reactivate shelved clinical-stage cell and gene therapy programs. The platform is designed to list available programs, generate AI-enhanced profiles, and support faster due diligence connections with investors and developers. The initiative targets therapies that have been deprioritized not for lack of clinical efficacy but due to market viability constraints. Organizers estimate there may be 50–100 such discontinuations and aim to reduce friction in re-licensing and re-development. For the CGT sector, CGTxchange formalizes how data packaging and re-scoring can translate clinical-stage evidence into renewed investment and development pathways.